Skin News and Research

RSS

Rib-X Pharmaceuticals presents positive preclinical data for delafloxacin at ICAAC Conference

Rib-X Pharmaceuticals, Inc., a development-stage antibiotics company with a broad product pipeline based on its innovative discovery platform, today announced the presentation of positive preclinical data for delafloxacin in four poster sessions at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

14 Sep 2010

New electronic sensor detects pressure exerted by 20 milligram bluebottle fly carcass

The light, tickling tread of a pesky fly landing on your face may strike most of us as one of the most aggravating of life's small annoyances. But for scientists working to develop pressure sensors for artificial skin for use on prosthetic limbs or robots, skin sensitive enough to feel the tickle of fly feet would be a huge advance. Now Stanford researchers have built such a sensor.

14 Sep 2010

Earthy or musty odors along with cyanobacteria may indicate presence of harmful cyanotoxins in lakes

Earthy or musty odors, along with visual evidence of blue-green algae, also known as cyanobacteria, may serve as a warning that harmful cyanotoxins are present in lakes or reservoirs. In a newly published USGS study of cyanobacterial blooms in Midwest lakes, taste-and-odor compounds were found almost every time cyanotoxins were found, indicating odor may serve as a warning that harmful toxins are present.

14 Sep 2010

Sanofi Pasteur files Fluzone Intradermal influenza virus vaccine sBLA with FDA

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today that it has filed a Supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) for Fluzone® Intradermal (Influenza Virus Vaccine). The file has been accepted by the FDA and an action date is anticipated in the first half of 2011.

From BD (Becton, Dickinson and Company) 14 Sep 2010

Laser acupuncture a plausible treatment for depression

Acupuncture produces significant changes in parts of the brain that regulate emotional states and is a biologically plausible treatment for depression and other neuropsychiatric disorders, Australian researchers have shown for the first time.

13 Sep 2010

Provectus's PV-10 Phase 2 data to be presented at 7th International Melanoma Research Congress

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announces that data from its Phase 2 PV-10 metastatic melanoma study will be presented at the 7th International Melanoma Research Congress in Sydney, Australia, on November 4, 2010 at 4:30 p.m., as part of the 4th Interdisciplinary Melanoma & Skin Cancer Centres Meeting,

13 Sep 2010

Genotoxic effects of exposure to disinfection by-products in indoor swimming pools

Swimming in indoor chlorinated pools may induce genotoxicity (DNA damage that may lead to cancer) as well as respiratory effects, but the positive health effects of swimming can be maintained by reducing pool levels of the chemicals behind these potential health risks, according to a new study published in a set of three articles online September 12 ahead of print in the peer-reviewed journal Environmental Health Perspectives (EHP).

13 Sep 2010

Wisdom teeth contain reservoir of tissues to create stem cells: Study

For most people, wisdom teeth are not much more than an annoyance that eventually needs to be removed. However, a new study appearing in the September 17 Journal of Biological Chemistry shows that wisdom teeth contain a valuable reservoir of tissue for the creation of stem cells; thus, everyone might be carrying around his or her own personal stem-cell repository should he or she ever need some.

13 Sep 2010

Sun tanning still in demand for Victorian teenagers: Survey

According to the latest survey Victorian teenagers, despite skin cancer warnings, are still keen on getting a sun tan. The online survey by SunSmart showed that young Victorians are significantly more sun-safe than they were when the Slip! Slop! Slap! campaign first started 30 years ago.

12 Sep 2010

MRSA infection hVISA linked to mortality

A MRSA infection with a reduced susceptibility to the potent antibiotic drug vancomycin is linked to high mortality, according to a Henry Ford Hospital study.

12 Sep 2010

InHealth continues support for Northwestern and Duke with follow-on grants of over $830,000

The Institute for Health Technology Studies (InHealth) has awarded two follow-on grants totaling more than $830,000 to research teams at Northwestern University and Duke University.

10 Sep 2010

John Theurer Cancer Center plays major role in FDA's fast tracking of ipilimumab for metastatic melanoma

Researchers from the John Theurer Cancer Center at Hackensack University Medical Center played an important role in a study that led to the Food & Drug Administration's (FDA) recent fast tracking of ipilimumab, a promising treatment for metastatic melanoma. The FDA based its decision largely on the results of a pivotal study published in the New England Journal of Medicine on August 19, 2010 – the same day the agency accepted Bristol-Myers Squibb's application for the drug's approval and granted the application priority review status.

10 Sep 2010

GBCAs carry new warnings on their labels about risk of NSF: FDA

The U.S. Food and Drug Administration is requiring that gadolinium-based contrast agents (GBCAs) carry new warnings on their labels about the risk of a rare and potentially fatal condition known as nephrogenic systemic fibrosis, if the drug is administered to certain patients with kidney disease.

10 Sep 2010

Candida Force program of detoxification and dietary recommendations effective for weight reduction

Early this month, the cover of First for Women magazine stopped Kathleen Kalaf in her tracks. The magazine featured an article about the connection between systemic Candida, or yeast overgrowth, and fat.

10 Sep 2010

Research into role of genetic variation in drug-induced hypersensitivity reactions

The International Serious Adverse Events Consortium (SAEC) announced today it will collaborate with The University of Liverpool (www.liv.ac.uk/pharmacogenetics) to research the genetics of a form of serious adverse drug reaction called hypersensitivity. These are thought to involve the body's immune system, and mostly involve serious skin rashes.

10 Sep 2010

Researchers to develop image analysis techniques for melanoma classification

Melanoma, the most serious form of skin cancer varies in size, shape and severity, and although pathologists and researchers often intuitively differentiate between types of melanomas, the variations have never been formally quantified and documented. A project involving RENCI and researchers in the University of North Carolina School of Medicine and the departments of computer science and statistics and operations research aims to change that by using image analysis techniques to improve melanoma classification.

10 Sep 2010

FDA approves Abreu BTT 700 System for temperature monitoring

Brain Tunnelgenix Technologies Corp. announced today that the U.S. Food and Drug Administration (FDA) has granted the company clearance to market its Abreu BTT 700 System for continuous temperature monitoring.

10 Sep 2010

Oxygen Biotherapeutics 2010 first quarter net loss increases to $3 million

Oxygen Biotherapeutics, Inc., a development stage biomedical company focused on developing oxygen-rich intravenous and topical products, today announced results for the fiscal year (FY) first quarter ended July 31, 2010.

10 Sep 2010

New melanoma drug in the pipeline from Plexxikon and Roche

Researchers from biotech company Plexxikon have found that their candidate drug for skin cancer melanomas can be administered more effectively in early stages of the disease.

9 Sep 2010

Aethlon Hemopurifier captures immunosuppressive exosomes from individuals with metastatic melanoma.

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that its researchers have demonstrated the ability of the Aethlon Hemopurifier® to capture immunosuppressive exosomes derived from individuals with metastatic melanoma.

9 Sep 2010

Skin News and Research

Rib-X Pharmaceuticals presents positive preclinical data for delafloxacin at ICAAC Conference

New electronic sensor detects pressure exerted by 20 milligram bluebottle fly carcass

Earthy or musty odors along with cyanobacteria may indicate presence of harmful cyanotoxins in lakes

Sanofi Pasteur files Fluzone Intradermal influenza virus vaccine sBLA with FDA

Laser acupuncture a plausible treatment for depression

Provectus's PV-10 Phase 2 data to be presented at 7th International Melanoma Research Congress

Genotoxic effects of exposure to disinfection by-products in indoor swimming pools

Wisdom teeth contain reservoir of tissues to create stem cells: Study

Sun tanning still in demand for Victorian teenagers: Survey

MRSA infection hVISA linked to mortality

InHealth continues support for Northwestern and Duke with follow-on grants of over $830,000

John Theurer Cancer Center plays major role in FDA's fast tracking of ipilimumab for metastatic melanoma

GBCAs carry new warnings on their labels about risk of NSF: FDA

Candida Force program of detoxification and dietary recommendations effective for weight reduction

Research into role of genetic variation in drug-induced hypersensitivity reactions

Researchers to develop image analysis techniques for melanoma classification

FDA approves Abreu BTT 700 System for temperature monitoring

Oxygen Biotherapeutics 2010 first quarter net loss increases to $3 million

New melanoma drug in the pipeline from Plexxikon and Roche

Aethlon Hemopurifier captures immunosuppressive exosomes from individuals with metastatic melanoma.

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News